Divi’s Lab Seeks Shareholders’ Nod For Re-Appointment Of Kiran S Divi As Chief Executive Officer
Capsules fall into a collection bin at a drug manufacturing plant in Goa (Photographer: Dhiraj Singh/Bloomberg)

Divi’s Lab Seeks Shareholders’ Nod For Re-Appointment Of Kiran S Divi As Chief Executive Officer

Bookmark

Drug firm Divis Laboratories Ltd. on Monday said it has sought shareholders' approval for the re-appointment of Kiran S Divi as the chief executive officer of the company.

"The board of directors, at its meeting held on Jan. 4, 2020, has decided to seek approval of shareholders by postal ballot for...re-appointment of Kiran S Divi as whole-time director and chief executive officer of the company," the drug firm said in a filing to Bombay Stock Exchange.

Also read: Divi’s Labs Vying For No. 2 Spot Among India’s Generics-Dominated Pharma Stocks

The shareholders' nod has also been sought for the appointment of KV Chowdary as an independent director of the company and re-appointment of Madhusudana Rao Divi as whole-time Director (Projects), the filing said.

"The voting through postal ballot and through e-voting will commence from Jan. 28, 2020 and shall end on Feb. 26, 2020. The results of the postal ballot will be declared on or before Feb. 28, 2020," the filing said. The shares of the company were trading at Rs 1,927 piece on BSE, up 0.78 percent from the previous close.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.